EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access

Oral Nalbuphine in Idiopathic Pulmonary Fibrosis–Associated Cough

Philip L Molyneaux, Nesrin Mogulkoc, Hakan Gunen, Anna Doboszynska, Michael Kreuter, Blue Neustifter, Vandana Mathur, James Cassella, CORAL Study Group

JAMA · 24.03.2026 · 335 (12) · 1050

DOI: 10.1001/jama.2025.26179 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA, erschienen am 24.03.2026. Verfasst von Philip L Molyneaux und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Heart and Lung Institute, Imperial College London, London, United Kingdom. Hauptthemen laut MEDLINE: Analgesics, Opioid, Cough, Idiopathic Pulmonary Fibrosis, Nalbuphine. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance For patients with idiopathic pulmonary fibrosis (IPF), cough impairs quality of life; effective treatments for IPF-associated cough are needed.

Objective

To determine if nalbuphine extended release (ER), a κ opioid receptor agonist and μ-opioid receptor antagonist, decreases cough compared with placebo in patients with IPF-associated cough. Design, Setting, and Participants In this randomized, double-blind, placebo-controlled phase 2b trial conducted at 52 sites in 10 countries, patients with IPF, chronic cough for at least 8 weeks, and a Cough Severity Numerical Rating Scale (0, no cough; 10, worst possible cough) score of 4 or higher were enrolled from February 2024 to February 2025, with last follow-up in April 2025. Statistical analyses were conducted from May to August 2025.

Intervention

Patients were randomized 1:1:1:1 to receive nalbuphine ER at doses of 27 mg, 54 mg, or 108 mg or placebo twice daily for 6 weeks. Main Outcomes and Measures The primary outcome was the relative change from baseline in 24-hour cough frequency (coughs/h), measured with a digital cough monitor, for nalbuphine ER compared with placebo at week 6. The key secondary outcome was the relative change from baseline in the patient-reported cough frequency (Evaluating Respiratory Symptoms in IPF cough subscale; scores range from 0-4, lower scores indicate lesser cough frequency) at week 6.

Results

Of the 223 patients screened, 165 were randomized (42, 43, 40, and 40 to receive nalbuphine ER 27 mg, 54 mg, and 108 mg, and placebo, respectively) and 160 were included in the primary analysis (median age, 71 [range, 51-85] years; 28.5% female). The baseline mean (SD) cough count was 28.3 (27.4) coughs/h. In the nalbuphine ER 27 mg, 54 mg, and 108 mg twice-daily groups, the mean relative decrease in the cough count and the absolute decrease in coughs/h were 47.9% (from 24.6 to 11.9; P = .008), 53.4% (from 28.0 to 14.9; P < .001), and 60.2% (from 31.5 to 11.9; P < .001), respectively, compared with placebo (16.9%; from 29.4 to 28.1 coughs/h). For the key secondary outcome of patient-reported cough frequency at week 6, the relative and absolute changes were −31.4% (from 2.3 to 1.5; P = .14), −40.6% (from 2.6 to 1.4; P = .004), and −40.2% (from 2.4 to 1.4; P < .005) in the 27-mg, 54-mg, and 108-mg groups, respectively, compared with –21.9% (from 2.6 to 1.9) with placebo. Conclusions and Relevance For patients with IPF-associated chronic cough, all 3 doses of nalbuphine ER reduced objective cough frequency and the 2 higher doses improved patient-reported cough frequency at 6 weeks. Trial Registration ClinicalTrials.gov Identifier: NCT05964335

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidCoughIdiopathic Pulmonary FibrosisNalbuphineAgedFemaleHumansMaleMiddle AgedAdministration, OralDelayed-Action PreparationsDouble-Blind MethodReceptors, Opioid, kappaReceptors, Opioid, muAged, 80 and overSeverity of Illness IndexPatient Reported Outcome MeasuresTreatment Outcome

Substanzen

Analgesics, OpioidDelayed-Action PreparationsNalbuphineReceptors, Opioid, kappaReceptors, Opioid, mu

Autor:innen und Institutionen

  • National Heart and Lung Institute, Imperial College London, London, United Kingdom.
  • Royal Brompton & Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
  • Ege University Hospital, İzmir, Turkey.
  • Health Sciences University, Süreyyapaşa Research and Training Center for Chest Diseases and Thoracic Surgery, Istanbul, Turkey.
  • University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.
  • Warmińsko-Mazurskie Centrum Chorób Płuc, Olsztyn, Poland.

Zitieren

APA

Molyneaux, P. L., Mogulkoc, N., Gunen, H., Doboszynska, A., Kreuter, M., Neustifter, B., Mathur, V., Cassella, J., & CORAL Study Group (2026). Oral Nalbuphine in Idiopathic Pulmonary Fibrosis–Associated Cough. JAMA, 335(12), 1050. https://doi.org/10.1001/jama.2025.26179

Vancouver

Molyneaux PL, Mogulkoc N, Gunen H, Doboszynska A, Kreuter M, Neustifter B, et al. Oral Nalbuphine in Idiopathic Pulmonary Fibrosis–Associated Cough. JAMA. 2026;335(12):1050. doi:10.1001/jama.2025.26179

BibTeX
@article{Molyneaux2026,
  author = {Molyneaux, Philip L and Mogulkoc, Nesrin and Gunen, Hakan and Doboszynska, Anna and Kreuter, Michael and Neustifter, Blue and Mathur, Vandana and Cassella, James and CORAL Study Group, CORAL Study Group},
  title = {Oral Nalbuphine in Idiopathic Pulmonary Fibrosis–Associated Cough},
  journal = {JAMA},
  year = {2026},
  volume = {335},
  number = {12},
  pages = {1050},
  doi = {10.1001/jama.2025.26179}
}
Kostenlos starten →